ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in several solid tumors including brain metastases, but single agent ICIs have failed to improve outcome in recurrent (GBM). This study evaluated the safety of anti-CTLA-4 (IPI) and anti-PD-1 (NIVO) ICIs alone or in combina...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Gilbert, Mark, Zhang, Peixin, Sloan, Andrew, Aldape, Kenneth, Wu, Jing, Rogers, Lisa, Wen, Patrick, Barani, Igor, Iwamoto, Fabio, Raval, Raju, Voloshin, Alfredo, de Groot, John, Won, Minhee, Mehta, Minesh P
Format: Artigo
Language:Inglês
Published: Oxford University Press 2018
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216145/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.024
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items